Neratinib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anatomic Stage I Breast Cancer
Conditions
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Trial Timeline
May 30, 2024 → Apr 30, 2031
NCT ID
NCT05919108About Neratinib
Neratinib is a phase 2 stage product being developed by Puma Biotechnology for Anatomic Stage I Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05919108. Target conditions include Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05919108 | Phase 2 | Recruiting |
| NCT04781374 | Phase 2 | Withdrawn |
| NCT03812393 | Phase 2 | UNKNOWN |
| NCT00878709 | Phase 3 | Completed |
| NCT00864487 | Phase 1 | Completed |
| NCT00814060 | Phase 1 | Completed |
| NCT00757809 | Phase 1 | Completed |
| NCT00550212 | Phase 1 | Completed |
| NCT00498745 | Phase 1 | Completed |
| NCT00397046 | Phase 1 | Completed |
| NCT00380328 | Phase 1 | Completed |
| NCT00300781 | Phase 2 | Completed |
| NCT00366600 | Phase 1 | Completed |
| NCT00146172 | Phase 1 | Completed |
Competing Products
13 competing products in Anatomic Stage I Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Niraparib Tosylate Monohydrate | Eli Lilly | Phase 1 | 33 |
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 52 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 41 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 52 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 32 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 51 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen | Pfizer | Phase 2 | 51 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 32 |
| Aromatase Inhibition Therapy | Bristol Myers Squibb | Pre-clinical | 22 |
| Pelareorep + Retifanlimab | Incyte | Phase 2 | 49 |
| Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody | Imugene | Phase 1 | 25 |
| Ivermectin + Balstilmab + Pembrolizumab | Agenus | Phase 1/2 | 33 |